Cargando…

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer

CDK4 is emerging as a target in KRAS-mutant non-small cell lung cancer (NSCLC). We demonstrate that KRAS-mutant NSCLC cell lines are initially sensitive to the CDK4/6 inhibitor palbociclib, but readily acquire resistance associated with increased expression of CDK6, D-type cyclins and cyclin E. Resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haines, Eric, Chen, Ting, Kommajosyula, Naveen, Chen, Zhao, Herter-Sprie, Grit S., Cornell, Liam, Wong, Kwok-Kin, Shapiro, Geoffrey I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114982/ https://www.ncbi.nlm.nih.gov/pubmed/30167080 http://dx.doi.org/10.18632/oncotarget.25803

Ejemplares similares

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
por: Herter-Sprie, Grit S., et al.
Publicado: (2013)

The nuclear import of ribosomal proteins is regulated by mTOR
por: Kazyken, Dubek, et al.
Publicado: (2014)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
por: Ghosh, Arindam P., et al.
Publicado: (2015)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice
por: Shi, Xiaofang, et al.
Publicado: (2022)

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
por: Hasan, Md. Nabiul, et al.
Publicado: (2014)

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
por: Yang, Zhang, et al.
Publicado: (2022)

Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy
por: Cayo, Angel, et al.
Publicado: (2023)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice
por: Bajwa, Preety, et al.
Publicado: (2016)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
por: Brana, Irene, et al.
Publicado: (2017)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition
por: Gopalan, Priya K., et al.
Publicado: (2018)

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA(+) oral cancers
por: Yamaguchi, Kosuke, et al.
Publicado: (2016)

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
por: Lee, J. Scott, et al.
Publicado: (2015)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

Cis-acting elements in its 3′ UTR mediate post-transcriptional regulation of KRAS
por: Kim, Minlee, et al.
Publicado: (2016)

HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
por: Li, Zhipeng, et al.
Publicado: (2023)

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling
por: Luo, Yuan-Deng, et al.
Publicado: (2022)

Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation
por: Le Rolle, Anne-France, et al.
Publicado: (2016)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Posttranscriptional regulation of gene expression—adding another layer of complexity to the DNA damage response
por: Boucas, Jorge, et al.
Publicado: (2012)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

The impact of the MYB-NFIB fusion proto-oncogene in vivo
por: Mikse, Oliver R., et al.
Publicado: (2016)

Vascularization in mTOR Mouse Mutants: An Effort Not in Vein
por: Elziny, Soad, et al.
Publicado: (2023)

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
por: Mahoney, C L, et al.
Publicado: (2009)

FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC
por: Zhang, Dan, et al.
Publicado: (2019)

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
por: Yang, Zhang, et al.
Publicado: (2021)

Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines
por: Reschke, Robin, et al.
Publicado: (2022)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models
por: Herter-Sprie, Grit S., et al.
Publicado: (2014)

mTOR Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer
por: Cong, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fme6g1ks7qg8dafpd0jji07ide